This week's OncoAlert 🚨 Newsletter is packed with practice-changing data: REGISTER TO GET IT 👉 The latest oncology news, trials, and practice-changing data — all in one place. 🔴 **LUNG:** DeLLphi-305 shows an OS benefit with **tarlatamab + durvalumab** in extensive-stage SCLC. Plus, new insights into **lazertinib** resistance/ctDNA clearance and **osimertinib** in uncommon EGFR mutations. 🟠 **GI:** Promising Phase 1 data explore **L-glutamine + gemcitabine/nab-paclitaxel** in advanced pancreatic cancer. 🔵 **GU:** New data on perioperative treatment strategies in **high-risk prostate cancer** and fracture risk with **abiraterone**. 🟣 **BREAST:** New insights into pCR with neoadjuvant THP in **HER2+ disease** and biomarkers in **stage I TNBC**. 🌍 **PLUS:** Meet **AcuVox** — a free platform helping oncology professionals track the trials, treatments, and topics generating the most attention at major cancer congresses. 👉 **Stay informed. Stay ahead. Read this week’s OncoAlert Newsletter.** #OncoAlert# #Oncology# #CancerResearch# #LungCancer# #BreastCancer# #ProstateCancer# #PancreaticCancer# @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @LoiSher @JaniceTNBCmets @montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @sonpavde @drenriquegrande @tompowles1 @cdanicas @nataliagandur @realbowtiedoc @Onco_Cifu88 @scocmem @FernandoOnco @ElisaAgostinett @to_be_elizabeth @Erman_Akkus @MarioBalsaMD @DrMirallas @GIMedOnc @UOzkerim @DrRishabhOnco @PaulJiL @DaisukeKotani @DraMartinezLago @p_ciracimd @BenWestphalen @CentralParkWMD @graokane @amandaNizamMD @DrVilmaPBarcia